Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

You may be eligible if

• Grade II to IV GVHD
• Clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea.
• History of allogeneic hematopoietic cell transplant (HCT).
• Patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant.
• Patients must have adequate renal, hepatic, cardiac function and hematologic values